Mostrando 2 resultados de: 2
Filtros aplicados
Origen
scopus(2)
Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?
ArticleAbstract: The present study aimed to assess the tolerance and efficacy of rituximab (RTX), a chimeric IgG1 monPalabras claves:CD20, Pharmacogenomics, Rheumatoid Arthritis, rituximab, Sjögren's syndrome, systemic lupus erythematosusAutores:Anaya J.M., Claudio Galarza, Mantilla R.D., Pineda-Tamayo R., Rojas-Villarraga A., Rueda J.C., Tobón G.J., Valencia D., Zurita L.Fuentes:scopusThe administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus
ReviewAbstract: Background: In Latin America, the medical attention directed to systemic autoimmune diseases competePalabras claves:Autores:Cardiel M.H., Cervera R., Claudio M. Galarza-Maldonado, Doukh N., Kourilovitch M.R., Molineros J.E., Soroka N.F., Yagur V.Y., Zurita L.Fuentes:scopus